Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Maxim Seeks Ceplene Development Partner After FDA Request For More Data

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA indicates that approval of Ceplene for the treatment of acute myeloid leukemia would require confirmatory Phase III trial, Maxim says. The company previously withdrew an NDA for use of the oncologic in advanced malignant melanoma.
Advertisement

Related Content

EpiCept AML Drug Gets “Exceptional Circumstances” Stamp From EU Regulators
EpiCept AML Drug Gets “Exceptional Circumstances” Stamp From EU Regulators
Maxim Withdraws Ceplene Advanced Malignant Melanoma NDA
Maxim's Ceplene Fails Trial In Advanced Malignant Melanoma
Maxim's Ceplene Fails Trial In Advanced Malignant Melanoma

Topics

Advertisement
UsernamePublicRestriction

Register

PS060901

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel